Publications

See Publication

ASCO 2020

Results of a Completed Phase 1 Study of LAM-002 (Apilimod Dimesylate), a First-in-Class Phosphatidylinositol-3-Phosphate 5 Kinase (PIKfyve) Inhibitor, Administered as Monotherapy or With Rituximab or Atezolizumab to Patients with Previously Treated Follicular Lymphoma or Other B-cell Cancers

Catherine S Diefenbach, Jonathon B Cohen, Wael A Harb, Stephen M Ansell, Loretta J Nastoupil, Jeremy S Abramson, Nehal J Lakhani, Marshall T Schreeder, Taimur Sher, Dipti Patel-Donnelly, David M Aboulafia, Candace Fuchs, Darrell Nix, Sean Landrette, Patricia S Graham, Lydia B King, Peter R Young, Langdon L Miller, Henri Lichenstein, Sarah C Rutherford

See Publication

Topical Rapamycin in Patients With Facial Angiofibromas

Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex

Mary Kay Koenig, Cynthia S. Bell, Adelaide A. Hebert, Joan Roberson, Joshua A. Samuels, John M. Slopis, Patti Tate, Hope Northrup

See Publication

ASH 2019

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Neil Beeharry, Sean Landrette, Jeff Grotzke, Sophia Gayle, Marylens Hernandez, Stephanie Halene, Peter Young, Langdon Miller, Tian Xu, Jonathan Rothberg, Henri Lichenstein

See Publication

LAM-003 for treatment of AML

LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Neil Beeharry, Sean Landrette, Sophia Gayle, Marylens Hernandez, Jeff E. Grotzke, Peter R. Young, Paul Beckett, Xuan Zhang, Bing Z. Carter, Michael Andreeff, Stephanie Halene, Tian Xu, Jonathan Rothberg, Henri Lichenstein

Supplemental methods, figures, and data
See Publication

Identification of apilimod.

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg and Henri Lichenstein

Supplemental methods, figures, and data
See Publication

B-cell non-Hodgkin lymphoma.

B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg and Henri Lichenstein

See Publication

Targeted therapy in lymphoma.

Toward autophagy-targeted therapy in lymphoma

Lapo Alinari

See Publication

ASH 2017

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, Catherine S Diefenbach, Nehal Lakhani, Sarah C Rutherford, Marshall T Schreeder, Stephen M. Ansell, Taimur Sher, David M Aboulafia, Jonathon B Cohen, Darrell Nix, Sean Landrette, Kate Flanders, Langdon L Miller, Henri Lichenstein and Jeremy S. Abramson